ALKBH5 and schizophrenia: Therefore, we proposed that ALKBH5 and HTR1B may serve as potential blood biomarkers for diagnosing and individualizing pharmacotherapy for patients with schizophrenia, highlighting a novel avenue for therapeutic targeting.